Clover Biopharmaceuticals announces the construction of a new
CHENGDU, China, January 05, 2022 (GLOBE NEWSWIRE) – Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing new vaccines and biological therapy candidates, today announced that it has started construction of a new R&D center at Zhangjiang Biotech and Pharmaceutical Industrial Base, dubbed “Zhangjiang Pharma Valley”, located in the Zhangjiang Hi-Tech Park in Pudong, Shanghai. The Zhangjiang Pharmaceutical Valley is one of China’s major biotechnology hubs and is home to more than 1,000 innovative biotechnology and biopharmaceutical companies.
Clover has access to over 25,000 square meters of real estate to build a state-of-the-art facility that is expected to include new preclinical research lab facilities, manufacturing process development labs and a pilot GMP manufacturing facility . Construction of the R&D facilities is expected to be completed in the second quarter of 2022 and the entire R&D center is expected to be completed in the second half of 2022. Clover intends to recruit hundreds of new hires into the talent pool. from the region to complete the Clover team. existing R&D capabilities and accelerate the development of several new product candidates.
Joshua Liang, CEO of Clover Biopharmaceuticals said, “The creation of a new R&D center in Shanghai will allow us to expand our R&D capabilities and accelerate our innovation pipeline. Going forward, we plan to establish additional R&D centers around the world as we progress in the discovery and development of new, innovative product candidates.
The groundbreaking ceremony was attended by many partners and guests, including representatives of the Shanghai Municipal Economic and Information Technology Commission, the Shanghai Pudong New Zone government and the Shanghai administration. Shanghai Zhangjiang City of Science.
About Clover Biopharmaceuticals
Clover Biopharmaceuticals is a global clinical-stage biotechnology company engaged in the development of new vaccines and biological therapeutic candidates. The Trimer-Tag ™ technology platform is a product development platform for the creation of new vaccines and biological therapies. Clover leveraged the Trimer-Tag ™ technology platform to become a developer of COVID-19 vaccines and created SCB-2019 (CpG 1018 / Alum) to combat the COVID-19 pandemic caused by SARS-CoV -2.
For more information, please visit our website: www.cloverbiopharma.com and follow the company on LinkedIn.
Clover forward-looking statements
This press release contains certain forward-looking statements and information concerning us and our subsidiaries which are based on the beliefs of our management as well as on the assumptions made by and information currently available to our management. When used in this [document], the words “aim”, “anticipate”, “believe”, “could”, “estimate”, “expect”, “go ahead”, “intend”, “could”, “Could”, “should”, “plan”, “potential”, “foresee”, “plan”, “seek”, “should”, “will”, “would” and the negative of these words and other expressions Similar, with respect to us or our management, are intended to identify forward-looking statements.
Forward-looking statements are based on our current expectations and assumptions about our business, the economy and other future conditions. We do not guarantee that these expectations and assumptions will prove to be correct. Because forward-looking statements relate to the future, they involve inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our results may differ materially from those contemplated by forward-looking statements. They do not constitute statements of historical fact nor guarantees or assurances of future performance. We therefore recommend that you do not place undue reliance on these forward-looking statements. Any forward-looking statement we make in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to vary may occur from time to time, and we cannot predict all of them. Participating in the requirements of applicable laws, rules and regulations, we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements contained in this document are qualified by reference to this cautionary statement.
Senior Vice-President, Public Affairs
Vice-President, Investor Relations